References
- Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719–1730.
- World Health Organisation. Obesity and overweight. [cited 2021 Jul 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- Rosenberg J, Jacob J, Desai P, et al. Incretin hormones: pathophysiology risk factors and potential targets for type 2 diabetes. J Obes Metab Synd. 2021; 30: 233–247.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
- Verma S, Bain SC, Buse JB, et al. Occurrence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events. A post hoc analysis of a randomized clinical trial. JAMA Cardiol. 2019;4:1214–1220.
- Ard J, Fitch A, Fruh S, et al. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38:2821–2839.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.
- lTuricchi J, O’Driscoll R, Finlayson G, et al. Association between the proportion of free-fat mass loss during weight loss, changes in appetite, and subsequent weight change: results from a randomized 2-stage dietary intervention trial. Am J Clin Nutr. 2020;111:536–544.
- Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15:181–187.
- Berthoud H-R, Seely RJ, Roberts SB. Physiology of energy intake in the weight-reduced state. Obesity. 2021;29(Suppl1):S25–30.
- Feingold KR. Obesity and dyslipidemia – endotext – NCBI bookshelf. [cited 2021 Jul 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305895/
- Liu Y, Zhang X, Chai S, et al. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2019;2019:1534365.
- Wu S, Wang J, Jing L, et al. A diabetic patient complicated with pancreatic cancer after using liraglutide: a case report. Front Endocrinol (Lausanne). 2020;11:608966.
- Seviiri M, Lynch BM, Hodge AM, et al. Resting heart rate, temporal changes in resting heart rate, and overall and cause-specific mortality. Heart. 2018;104:1075–1085.
- Böhm M, Schumacher H, Teo KK, et al. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020;41:231–238.
- Neeland IJ, Marso SP, Ayers CR, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9:595–605.
- Davies MJ, Aonne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20:734–739.
- Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–1409.
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized trial. Int J Obes (London). 2013; 37: 1443–1451.
- FDA US Food & Drug Administration. FDA drug safety communication: FDA recommends against the continued use of Meridia (sibutramine). [cited 2021 Dec 8]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-continued-use-meridia-sibutramine